[go: up one dir, main page]

RU2018104155A - NEUROPROTECTIVE MEANS - Google Patents

NEUROPROTECTIVE MEANS Download PDF

Info

Publication number
RU2018104155A
RU2018104155A RU2018104155A RU2018104155A RU2018104155A RU 2018104155 A RU2018104155 A RU 2018104155A RU 2018104155 A RU2018104155 A RU 2018104155A RU 2018104155 A RU2018104155 A RU 2018104155A RU 2018104155 A RU2018104155 A RU 2018104155A
Authority
RU
Russia
Prior art keywords
neuroprotective agent
neuroprotective
daily dosage
agent according
magnolol
Prior art date
Application number
RU2018104155A
Other languages
Russian (ru)
Other versions
RU2018104155A3 (en
Inventor
Ксения Андреевна Тукмачева
Валерий Георгиевич Сергеев
Елена Сергеевна Заколюкина
Original Assignee
Ксения Андреевна Тукмачева
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ксения Андреевна Тукмачева filed Critical Ксения Андреевна Тукмачева
Priority to RU2018104155A priority Critical patent/RU2018104155A/en
Publication of RU2018104155A3 publication Critical patent/RU2018104155A3/ru
Publication of RU2018104155A publication Critical patent/RU2018104155A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (4)

1. Нейропротективное средство состоит из следующих компонентов растительного происхождения: магнолол, хонокиол, генистеин, которые смешиваются последовательно.1. The neuroprotective agent consists of the following components of plant origin: magnolol, honokiol, genistein, which are mixed in series. 2. Нейропротективное средство по п. 1, отличающееся тем, что суточная дозировка магнолола составляет от 100 до 5000 мг.2. The neuroprotective agent according to claim 1, characterized in that the daily dosage of magnolol is from 100 to 5000 mg. 3. Нейропротективное средство по п. 1, отличающееся тем, что суточная дозировка хонокиола составляет от 100 до 5000 мг.3. The neuroprotective agent according to claim 1, characterized in that the daily dosage of honokiol is from 100 to 5000 mg. 4. Нейропротективное средство по п. 1, отличающееся тем, что суточная дозировка генистеина составляет от 5 до 1000 мг.4. The neuroprotective agent according to claim 1, characterized in that the daily dosage of genistein is from 5 to 1000 mg.
RU2018104155A 2018-02-02 2018-02-02 NEUROPROTECTIVE MEANS RU2018104155A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2018104155A RU2018104155A (en) 2018-02-02 2018-02-02 NEUROPROTECTIVE MEANS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018104155A RU2018104155A (en) 2018-02-02 2018-02-02 NEUROPROTECTIVE MEANS

Publications (2)

Publication Number Publication Date
RU2018104155A3 RU2018104155A3 (en) 2019-08-05
RU2018104155A true RU2018104155A (en) 2019-08-05

Family

ID=67586488

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018104155A RU2018104155A (en) 2018-02-02 2018-02-02 NEUROPROTECTIVE MEANS

Country Status (1)

Country Link
RU (1) RU2018104155A (en)

Also Published As

Publication number Publication date
RU2018104155A3 (en) 2019-08-05

Similar Documents

Publication Publication Date Title
MX2021001091A (en) Methods for treatng huntington's disease.
MX369415B (en) Concentrated personal cleansing compositions.
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
EA201071291A2 (en) NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYATRIC DISORDERS
MX2016011897A (en) Compositions of selenoorganic compounds and methods of use thereof.
CL2012003538A1 (en) Specific anti-s100a4 antibody with antiangiogenic activity or a fragment thereof produced by a hybridoma selected from the group ecacc 10022401, ecacc 11051801, ecacc 11051802, ecacc 11051803 and ecacc 11051804; cell lines that produce it; pharmaceutical composition comprising it; use of the antibody to treat disease associated with inflammation.
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
BR112017001192A2 (en) sugar compositions for tabletting by direct compression
MX2016007313A (en) Use of benzimidazole-proline derivatives.
MX371306B (en) Concentrated personal cleansing compositions and uses.
TR201902741T4 (en) Personal Cleaning Compositions
WO2015171738A3 (en) Fragrance compositions
RU2014130012A (en) MALVA NEGLECTA EXTRACT COMPOSITIONS
EP4574832A3 (en) Dantrolene prodrugs and methods of their use
EP3646855C0 (en) ORAL SOLID PREPARATION COMPOSITION CONTAINING PROTON PUMP INHIBITOR, ORAL SOLID PREPARATION THEREOF AND MANUFACTURING PROCESS THEREOF
CL2015000415A1 (en) Pntx synthetic peptide (19) pharmaceutical compositions and use
CL2007003847A1 (en) COMPOUNDS DERIVED FROM PYRIMIDINS 2,4,5 TRI-SUBSTITUTES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CANCER.
RU2018104155A (en) NEUROPROTECTIVE MEANS
MX2019014604A (en) Nasal composition.
CL2016003102A1 (en) 1h-1,8-naphthyridin-2-ones as antiproliferative compounds.
IL263717B (en) Mixture comprising at least dihydro-5-pentyl-2(3h)-furanone and 2,4-dimethyl-4-phenyltetrahydrofuran and its use to mask bad odours
PH12019501225A1 (en) Modified streptomyces fungicidicus isolates and their use
EA201990162A1 (en) PHARMACEUTICAL COMPOSITIONS
EA201691422A1 (en) ORIGINALLY FALLING TABLETED MEMANTINE COMPOSITIONS
CL2008000491A1 (en) COMPOUNDS DERIVED FROM 1,1-DIOXO-1-TIA-DIAZA-DIBENZO CICLOHEPTENO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; AND ITS USE TO TREAT HEPATITIS C.

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190827